People: Aegerion Pharmaceuticals Inc (AEGR.O)
AEGR.O on Nasdaq
60.11USD
20 May 2013
60.11USD
20 May 2013
Price Change (% chg)
$-1.46 (-2.37%)
$-1.46 (-2.37%)
Prev Close
$61.57
$61.57
Open
$61.71
$61.71
Day's High
$62.21
$62.21
Day's Low
$59.90
$59.90
Volume
545,044
545,044
Avg. Vol
624,627
624,627
52-wk High
$63.72
$63.72
52-wk Low
$12.86
$12.86
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
David Scheer |
60 | 2005 | Independent Chairman of the Board |
Marc Beer |
48 | 2010 | Chief Executive Officer, Director |
Mark Fitzpatrick |
49 | 2011 | Chief Financial Officer |
Anne Cook |
50 | 2011 | Senior Vice President, General Counsel, Secretary |
Martha Carter |
59 | 2011 | Chief Regulatory Officer and Senior Vice President |
Mark Sumeray |
46 | 2011 | Chief Medical Officer |
Anne VanLent |
2013 | Director | |
Sol Barer |
2011 | Independent Director | |
Antonio Gotto |
76 | 2006 | Independent Director |
Sandford Smith |
65 | 2012 | Independent Director |
Paul Thomas |
56 | 2011 | Independent Director |
Amanda Murphy |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
David Scheer |
Mr. David I. Scheer is Independent Chairman of the Board of Aegerion Pharmaceuticals Inc., since February 2005. He is a co-founder of Aegerion. Since 1981, Mr. Scheer has served as President at Scheer & Company, Inc., a company that provides corporate strategic advisory services in the life sciences industry. Mr. Scheer serves as the Chairman of the Board of Tengion, Inc. and Achillion Pharmaceuticals, Inc. Mr. Scheer also serves on the boards of directors of several private companies. Mr. Scheer is also a member of the Advisory Committee to the Harvard Malaria Initiative and the Leadership Council for the Harvard School of Public Health. Mr. Scheer holds an A.B. cum laude from Harvard College and an M.S. from Yale University. |
Marc Beer |
Mr. Marc D. Beer has been appointed as the Chief Executive Officer and Director of Aegerion Pharmaceuticals Inc., since August 2010. Prior to joining Aegerion, from April 2000 to November 2007, Mr. Beer served as the President and Chief Executive Officer of ViaCell, Inc., a cellular therapy company. Prior to joining ViaCell, he held marketing and business development roles at Genzyme Corporation, most recently serving as Vice President of Global Marketing. Prior to joining Genzyme, he served as Vice President, Sales and Marketing at Biostar, Inc. and held a variety of sales and marketing roles in the pharmaceutical and diagnostic devices divisions of Abbott Laboratories. Mr. Beer holds a B.S. from Miami University (Ohio). |
Mark Fitzpatrick |
Mr. Mark J. Fitzpatrick is Chief Financial Officer of Aegerion Pharmaceuticals Inc., since May 2011. From July 2007 to May 2011, Mr. Fitzpatrick served as Vice President and Chief Financial Officer of Proteon Therapeutics, Inc., a privately held biopharmaceutical company engaged in the development of products to treat cardiovascular disease. From August 2005 to May 2007, Mr. Fitzpatrick was Vice President, Chief Financial Officer, Treasurer and Assistant Secretary for RenaMed Biologics, Inc. Mr. Fitzpatrick previously held Chief Financial Officer positions with Dynogen Pharmaceuticals, Worldstreet Corporation, and Diacrin. Prior to those positions, Mr. Fitzpatrick held various financial management positions with Repligen Corp. and was a senior auditor with Arthur Andersen & Co. Mr. Fitzpatrick received his B.S. degree in accounting from Boston College and was awarded a CPA certificate from the Commonwealth of Massachusetts in 1987. |
Anne Cook |
Ms. Anne Marie Cook has been appointed as Senior Vice President, General Counsel, Secretary of Aegerion Pharmaceuticals, Inc., since December 5, 2011. From December 2008 to December 2011, Ms. Cook was a partner at Choate Hall & Stewart LLP, where she represented both private and public corporations in the life sciences industry in structuring and negotiating strategic transactions and providing general legal support in connection with the research, development and commercialization of pharmaceutical products. From April 2007 to December 2008, Ms. Cook was a Principal at Miller Canfield P.L.C. From September 2005 until April 2007, Ms. Cook served as General Counsel and Senior Vice President, Business and Corporate Development, and Secretary of ViaCell, Inc., a biotechnology company. Prior to joining ViaCell, Ms. Cook spent thirteen years at Biogen Idec Inc., most recently as Vice President, Chief Corporate Counsel. Ms. Cook holds a B.S. degree in Biology from Tufts University and a J.D. degree from the University of Notre Dame Law School. |
Martha Carter |
Ms. Martha J. Carter is the Chief Regulatory Officer and Senior Vice President of Aegerion Pharmaceuticals, Inc., since February 2011. From January 2011 to February 2011, Ms. Carter served as Senior Vice President and Chief Regulatory Officer at Proteon Therapeutics, Inc., a privately held biopharmaceutical company, and from September 2006 to December 2010, she served as Senior Vice President, Regulatory Affairs and Quality Assurance, at Proteon Therapeutics, Inc. In both roles, Ms. Carter was responsible for Proteon’s worldwide regulatory and quality functions. From September 2002 to April 2006, Ms. Carter was Senior Vice President, Regulatory Affairs, for Trine Pharmaceuticals. Prior to joining Trine, Ms. Carter was Vice President, Regulatory Affairs for GelTex Pharmaceuticals, Inc. Ms. Carter received her B.A. degree in biology from Northeastern University. |
Mark Sumeray |
Dr. Mark Sumeray, MD, MS, FRCS, has been appointed as Chief Medical Officer of Aegerion Pharmaceuticals, Inc., since August 2011. From November 2009 to July 2011, Dr. Sumeray served as Vice President, Cardiovascular/Metabolics U.S. Medical at Bristol-Myers Squibb, a pharmaceutical company. From December 2004 to November 2009, Dr. Sumeray held various positions at The Medicines Company, including Vice President and Business Unit Co-Leader, Vice President, Medical Business Development, and Vice President Clinical Development and Head of Medical Science. From September 2000 to October 2004, Dr. Sumeray served as worldwide Vice President of Clinical Development for the Ethicon Franchise of Johnson & Johnson. Dr. Sumeray received his B.Sc. degree in Physiology, his M.B.B.S. in medicine, and his M.D. in medicine, each from the University College London. Dr. Sumeray is a Fellow of the Royal College of Surgeons (FRCS) in the United Kingdom. |
Anne VanLent |
Ms. Anne M. VanLent is Director of Aegerion Pharmaceuticals, Inc. Ms. VanLent is currently the President of AMV Advisors, an advisory firm which she founded in 2008 to provide corporate strategy and financial consulting services to emerging growth life science companies. Previously, Ms. VanLent was Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. Prior to that, she was Executive Vice President, Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. Earlier in her career, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc. Ms. VanLent also currently serves as a member of the Board of Directors of Integra LifeSciences and Tranzyme Pharma, where she serves as Audit Chair. She has previously served as a member of the Board of Directors of Penwest Pharmaceuticals and i-STAT Corporation. |
Sol Barer |
Dr. Sol J. Barer, Ph.D. is an Independent Director of Aegerion Pharmaceuticals, Inc., since May 2011. Dr. Barer is currently the Managing Partner of SJBarer Consulting LLC. He previously served in various positions at Celgene Corporation (a biopharmaceutical company focused on the treatment of cancer and inflammatory diseases), including Chairman and Chief Executive Officer from May 2006 until June 2010, Executive Chairman from June 2010 until December 2010, and Non-Executive Chairman from January 2011 until June 2011. Prior to that, he held several other positions within Celgene, including President and Chief Operating Officer. Dr. Barer joined the Celanese Research Company in 1974 and formed the biotechnology group that was subsequently spun out to form Celgene. Dr. Barer currently serves on the Board of Directors of Amicus Therapeutics (a biopharmaceutical company focused on the development of novel small molecule drugs for the treatment of genetic diseases), InspireMD, Inc. (a medical device company focused on the development and commercialization of stent system technology), and several privately held biotechnology companies. Dr. Barer received a B.S. from Brooklyn College and a Ph.D. in Organic Chemistry from Rutgers University. |
Antonio Gotto |
Dr. Antonio M. Gotto, Jr., M.D., D.Phil., is an Independent Director of Aegerion Pharmaceuticals Inc., since January 2006. Dr. Gotto currently serves as Co-Chairman of the Board of Overseers of the Joan and Sanford I. Weill Medical College of Cornell University and Vice President of Cornell University. From January 1997 to December 2011, Dr. Gotto served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University. Previously, Dr. Gotto served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital. Dr. Gotto currently serves as a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences. Dr. Gotto is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association. Dr. Gotto holds a B.A. from Vanderbilt University, a D.Phil. from Oxford University in England, where he was a Rhodes Scholar, and an M.D. from Vanderbilt University School of Medicine. He completed his residency training at Massachusetts General Hospital in Boston, Massachusetts. |
Sandford Smith |
Mr. Sandford D. Smith has been appointed as an Independent Director of Aegerion Pharmaceuticals Inc., since January 2012. Mr. Smith is also a member of the Audit Committee of the Board of Directors. Mr. Smith is currently a Managing Director of Tullis Health Investors, which manages a family of funds and investments focusing on the healthcare industry. Prior to joining Tullis Health Investors in January 2012, Mr. Smith served from 1996 until 2011 in various senior and executive management positions at Genzyme Corporation, including most recently as Executive Vice President and President of Genzyme’s International Group with responsibility for the commercial activities for Genzyme’s products outside of the United States. Prior to joining Genzyme, Mr. Smith served from 1986 to 1996 as President and Chief Executive Officer and a Director of Repligen Corporation. Mr. Smith previously held a number of positions with Bristol-Myers Squibb Company from 1977 to 1986, including Vice President of Business Development and Strategic Planning for the Pharmaceutical Group. Mr. Smith currently serves as a director of BioBehavioral Diagnostics Company, a privately held company that manufactures and markets technologies for the diagnosis and management of neurological and psychiatric conditions, and serves as a Board of Trustees of Brigham and Women’s Hospital in Boston. Mr. Smith holds a B.Sc. degree from the University of Denver. |
Paul Thomas |
Mr. Paul G. Thomas has been appointed as an Independent Director of Aegerion Pharmaceuticals, Inc., since August 1, 2011. Mr. Thomas is also the chairman of the Audit Committee of the Board of Directors. Mr. Thomas is the founder, and since September 2009 has served as Chief Executive Officer, of Roka Bioscience, Inc., a privately held company principally engaged in the development and commercialization of molecular assays for biopharmaceutical processing, food safety and other industrial testing applications. From October 1998 until August 2008, Mr. Thomas served as Chairman, Chief Executive Officer and President of LifeCell Corporation, a publicly traded company that developed and marketed innovative tissue repair products for use in reconstructive, orthopedic and urogynecologic surgical procedures. LifeCell was acquired in 2008 by Kinetic Concepts, Inc. Prior to joining LifeCell, Mr. Thomas was President and Chief Operating Officer of the Pharmaceutical Products Division of Ohmeda Inc. (now Baxter PPD). Mr. Thomas is also a member of the Board of Directors of AbioMed, Inc., a provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Mr. Thomas received his M.B.A. degree with an emphasis in Marketing and Finance from Columbia University Graduate School of Business, and completed his postgraduate studies in Chemistry at the University of Georgia Graduate School of Arts and Science. He received his B.S. degree in Chemistry from St. Michael’s College in Vermont. |
Amanda Murphy |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
David Scheer |
-- |
Marc Beer |
2,131,520 |
Mark Fitzpatrick |
3,083,000 |
Anne Cook |
-- |
Martha Carter |
2,002,280 |
Mark Sumeray |
1,998,130 |
Anne VanLent |
-- |
Sol Barer |
-- |
Antonio Gotto |
-- |
Sandford Smith |
-- |
Paul Thomas |
-- |
Amanda Murphy |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
David Scheer |
0 | 0 |
Marc Beer |
0 | 0 |
Mark Fitzpatrick |
0 | 0 |
Anne Cook |
0 | 0 |
Martha Carter |
0 | 0 |
Mark Sumeray |
0 | 0 |
Anne VanLent |
0 | 0 |
Sol Barer |
0 | 0 |
Antonio Gotto |
0 | 0 |
Sandford Smith |
0 | 0 |
Paul Thomas |
0 | 0 |
Amanda Murphy |
0 | 0 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
